Page 3 - புதியது மருந்து பயன்பாடுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies -In July 2019, selinexor (XPOVIO®) was approved by the U.S. FDA and became the first and only XPO1 inhibitor indicated for the treatment of hematologic malignancies. -Selinexor has been approved in the U.S., Israel, UK, and EU countries. News provided by Share this article Share this article SHANGHAI and HONG KONG, July 13, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for selinexor, a first-in-class XPO1 inhibitor, for three indications: in combination with bortezomib and dexamethasone (XVd), or in combination w

New zealandSouth koreaKevin lynchJay meiAsia pacificKaryopharm therapeutics incAntengene corporationEuropean commissionDrug administrationChina national medical products administrationPrnewswire antengene corporation limitedAntengene corporation limitedConnective tissue oncology societyIsraeli ministry of healthMinistry of foodCorporation limited